Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cofirasersen - Ionis Pharmaceuticals

Drug Profile

Cofirasersen - Ionis Pharmaceuticals

Alternative Names: ENaC ASO - Ionis Pharmaceuticals; Generation 2.5 ENaC antisense oligonucleotide - Ionis Pharmaceuticals; Generation 2.5 ENaC ASOs - Ionis Pharmaceuticals; ION-827359; IONIS-ENAC-2.5Rx; IONIS-ENaCRx

Latest Information Update: 04 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Epithelial sodium channel antagonists; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 14 May 2021 Pharmacokinetics and safety data from a phase I/IIa trial in Cystic fibrosis presented at the International Conference of the American Thoracic Society (ATS-2021)
  • 13 May 2021 Ionis Pharmaceuticals terminates phase II trial in Chronic obstructive pulmonary disease in United Kingdom, Germany, Hungary and Czech Republic (Inhalation) (NCT04441788)
  • 04 Feb 2021 Ionis Pharmaceuticals completes a phase I/IIa trial in Cystic fibrosis in Germany and United Kingdom (Inhalation) (NCT03647228) (EudraCT2018-002621-27)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top